A trio of Senators called on Mylan Pharmaceuticals Monday to reimburse the Department of Defense for overcharging the department for EpiPens for years.
Sens. Chuck Grassley (R-Iowa), Richard Blumenthal (D-Conn.) and Amy Klobuchar (D-Minn.) say they are “alarmed that Mylan may have overcharged our military for this life-saving drug.”
“Given Mylan’s stated intent to properly reclassify the EpiPen, Mylan should take immediate action to ensure that service members, their families, and the federal government do not pay excessively for EpiPen,” they write. “Since it appears that due to Mylan’s misclassification the DoD was overcharged through its retail pharmacy network, what are Mylan’s plans to reimburse the DoD?”
The company, which has been under fire for the rising price of EpiPens, misclassified the drug as a “non-innovator multiple source drug,” which allowed the company to pay larger rebates for EpiPens. Recent reports have shown the Pentagon’s spending rose by millions because of the misclassification.
“If Mylan’s intention is to “move forward and bring resolution to all EpiPen Auto-Injector related matters,” it is imperative that you quickly resolve this additional discrepancy and take steps to refund our military for past overpayments,” the lawmakers add.